Cervical insufficiency (CI), responsible for 8% of preterm births (PB), is used to describe painless cervical dilation leading to recurrent second-trimester pregnancy losses/births of otherwise normal pregnancies. Structural weakness of cervical tissue was thought to cause or contribute to these adverse outcomes. The term has also been applied to women with one or two such losses/births or at risk for second-trimester pregnancy loss/birth. Cervical pessary and cervical cerclage are both considered as preventive treatments in women at risk for PB. This study aims to demonstrate that the cervical pessary could reduce the preterm birth rate before 37 weeks of gestation in women with prior PB due to cervical insufficiency or in women with prior PB and a short cervix in the current pregnancy.
Methods/Design: This is an open-label, pilot, multicentre, prospective, randomised controlled trial (RCT). Enrolees are women with singleton pregnancies and previous PB based on CI (primary intervention, \<16 weeks) or in case of previous PB and a short cervical length in current pregnancy ≤ 25 mm (secondary intervention, \<24 weeks). Women are randomised (1:1) either to cervical cerclage or pessary treatment. The primary outcome is the spontaneous preterm birth rate before 34 weeks of gestation. The sample size was calculated, as a pilot study, based on the estimated population that we will be able to recruit during the duration of the trial: 60 women, 30 for each group (cervical cerclage and cervical pessary group) to observe, at least a reduction in the PB rate \< 34 weeks from 34% to 27% in the pessary group, as does cerclage. Discussion: The outcome of this study will show the effectiveness of a cervical cerclage and of a cervical pessary in this group of patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Surgical procedure which consists of a strong suture being inserted into and around the cervix to close it.
The Arabin cervical pessary, which is CE-certified for preventing spontaneous preterm birth (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC). It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
Hospital Vall d'Hebron
Barcelona, Spain
Spontaneous delivery before 34 complete weeks
Spontaneous delivery before 34 complete weeks
Time frame: Before 34 weeks of gestation
Spontaneous delivery before 28 complete weeks
Spontaneous delivery before 28 complete weeks
Time frame: Before 28 weeks of gestation
Spontaneous delivery before 37 complete weeks
Spontaneous delivery before 37 complete weeks
Time frame: Before 37 weeks of gestation
Foetal and neonatal death
Foetal and neonatal death
Time frame: During pregnancy and during the first 28 days of newborn or NICU stay
Neonatal morbidity
Neonatal morbidity
Time frame: 28 days of newborn or during NICU stay
Maternal side effects
Maternal side effects
Time frame: During pregnancy
Maternal morbidity
Maternal morbidity
Time frame: during pregnancy
Number of participants with chorioamnionitis infection
Number of participants with chorioamnionitis infection
Time frame: During pregnancy
Hospitalisation for threatened preterm labour
Hospitalisation for threatened preterm labour
Time frame: During pregnancy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.